ストックスクリーナーアプリを入手
86.20
0.87%
0.74
アフターアワーズ：
85.30
-0.90
-1.04%
前日終値:
$85.46
開ける：
$85.23
24時間の取引高:
1.69M
Relative Volume:
0.93
時価総額：
$16.83B
収益：
$4.58B
当期純損益:
$870.87M
株価収益率:
19.59
EPS:
4.4
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
+0.41%
1か月 パフォーマンス:
+27.03%
6か月 パフォーマンス:
+20.76%
1年 パフォーマンス:
+33.89%
1日の値動き範囲:
$84.76
$86.37
1週間の範囲:
$84.41
$87.24
52週間の値動き範囲:
$53.56
$87.24
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
86.20 | 16.58B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold? - sg.finance.yahoo.com
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
Are Wall Street Analysts Predicting Incyte Stock Will Climb Or Sink? - Barchart.com
Incyte to Present at Upcoming Investor Conferences - MarketScreener
Will Incyte Corporation Reverse From Oversold ConditionsJuly 2025 Intraday Action & Daily Risk Controlled Trade Plans - metrotimes.co.kr
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers - Yahoo Finance
Incyte rises on results beat, lifted Jakafi guidance - MSN
Incyte Corp (INCY) Set to Outperform Market: Strong Financial Growth and Competitive Advantage - AInvest
Cancer Stock Soars While This China Tech Stock Heads To New Highs - Investor's Business Daily
Incyte CFO Christiana Stamoulis to Step Down in September - MSN
Stock Analysis | Incyte OutlookMixed Signals Amid Rising Price and Strong Fundamentals - AInvest
Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance
Incyte's 5.2% Surge on $270M Volume Ranks 430th Amid FDA Approval and Strategic Shifts - AInvest
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know - Yahoo Finance
Incyte stock hits 52-week high at 83.95 USD - Investing.com
The Top 5 Analyst Questions From Incyte’s Q2 Earnings Call - Yahoo Finance
Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight - Insider Monkey
Trapped Investors in Incyte Corporation Await Breakout SignalPortfolio Diversification Stock Ideas From Experts - beatles.ru
Incyte EVP Denton sells $45k in shares after option exercise - Investing.com Australia
Semerjian to lead Geron - BioCentury
Incyte EVP Denton sells $45k in shares after option exercise By Investing.com - Investing.com South Africa
Incyte (INCY) Analyst Rating: Wells Fargo Upgrades to Overweight - GuruFocus
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - The Manila Times
Mallinckrodt appoints Incyte’s Christiana Stamoulis as new CFO - Investing.com
Wells Fargo Upgrades Incyte to Overweight From Equalweight, Adjusts Price Target to $89 From $67 - MarketScreener
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis - BioSpace
Incyte CFO Christiana Stamoulis to step down in September - Investing.com
Incyte CFO Christiana Stamoulis to step down in September By Investing.com - Investing.com UK
Argus Research Adjusts Incyte Price Target to $90 From $75 - MarketScreener
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America - The Manila Times
Mizuho Securities Adjusts Incyte Price Target to $74 From $70 - MarketScreener
Incyte's (INCY) "Neutral" Rating Reiterated at UBS Group - MarketBeat
Is it the right time to buy Incyte Corporation stockUnlock powerful investment tools for free - Jammu Links News
What makes Incyte Corporation stock price move sharplyBuild wealth faster with expert stock picks - Jammu Links News
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer - Stocktwits
Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News - GuruFocus
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Benzinga
Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada
Barclays initiates coverage on Incyte stock with Overweight rating - Investing.com
Incyte's Stock Price Target Raised by RBC Capital to $72.00 - AInvest
Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus
Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - Jammu Links News
Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - MSN
Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Nigeria
Incyte stock price target raised to $72 from $68 at RBC Capital By Investing.com - Investing.com South Africa
Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada
Incyte stock price target raised to $60 from $52 at BMO Capital By Investing.com - Investing.com South Africa
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
Incyte Corp (INCY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Aug 15 '25 |
Sale |
86.81 |
277 |
24,046 |
33,200 |
2.44%
0.09%
大文字化:
|
ボリューム (24 時間):